FDA Approves Gilteritinib for Relapsed or Refractory AML With FLT3 Mutation
Nov 28
2018
The Food and Drug Administration approved gilteritinib (XOSPATA, Astellas Pharma US Inc.) for treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.
